Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS (Myfortic) versus prior maintenance therapy in proliferative lupus nephritis
2005-003070-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mycophenolate sodium in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Novartis. Primary endpoint: Daily corticosteroid dose over 24 months. Started Feb 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2005-003070-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003070-19.